BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/15/2014 1:17:00 PM | Browse: 902 | Download: 1904
| Category |
Transplantation |
| Manuscript Type |
Therapeutics Advances |
| Article Title |
Perspective of antiviral therapeutics for hepatitis C after liver transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Cheng-Maw Ho, Rey-Heng Hu and Po-Huang Lee |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Cheng-Maw Ho, MD, Department of Surgery, National Taiwan University Hospital, 7 Chun-Shan S Rd, Taipei 100, Taiwan. miningho@ntu.edu.tw |
| Key Words |
Hepatitis C; Recurrence; Liver transplantation; Therapeutics; Fibrosis |
| Core Tip |
Management of hepatitis C virus (HCV) recurrence after liver transplantation used to be a bothering issue due mostly to the interferon-based therapy. Current available data from treatment of chronic HCV infection shows promising results of interferon-free, or even ribavirin-free, pan-genotypic, all oral medications will soon reform the treatment of HCV recurrence after liver transplantation. |
| Publish Date |
2014-12-12 11:14 |
| Citation |
Ho CM, Hu RH, Lee PH. Perspective of antiviral therapeutics for hepatitis C after liver transplantation. World J Pharmacol 2014; 3(4): 193-198
|
| URL |
http://www.wjgnet.com/2220-3192/full/v3/i4/193.htm |
| DOI |
http://dx.doi.org/10.5497/wjp.v3.i4.193 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.